Icotrokinra Dosing Calculator
Icotrokinra (JNJ-2113): first-in-class oral peptide targeting the IL-23 receptor.
Pre-filled with the most-reported clinical reconstitution protocol for Icotrokinra. See how 1 mL and 2 mL of bacteriostatic water change concentration and syringe-draw volume, then adjust the calculator below for your own vial.
Quick answer · Clinical protocol
A 15 mg vial of Icotrokinra reconstituted with 2 mL of bacteriostatic water yields a concentration of 7.50 mg/mL. At that concentration, a 200 mg dose of Icotrokinra equals 2666.7 units on a U-100 insulin syringe (26.667 mL). Icotrokinra is typically administered once daily.
Icotrokinra reconstitution: 1 mL vs 2 mL bac water
Bacteriostatic water volume is flexible. Less water means higher concentration and smaller injection volumes; more water means lower concentration and easier dose precision. Both options below are valid for a 15 mg vial.
| BAC water added | Concentration | Volume per 200 mg dose | Draw on U-100 syringe (units) |
|---|---|---|---|
| 1 mL | 15.00 mg/mL | 13.333 mL | 1333.3 units |
| 2 mL | 7.50 mg/mL | 26.667 mL | 2666.7 units |
Calculate your Icotrokinra dose
Alternative Icotrokinra protocols
Beyond the default above, Icotrokinra is also reported in the following protocols. Use these as starting points and recalculate with the tool above.
Moderate-to-Severe Plaque Psoriasis (Phase 2b Highest Dose)
Clinical- Dose
- 100 mg orally twice daily
- Frequency
- Twice daily oral administration
- Duration
- 16 weeks evaluated in FRONTIER 1
Highest dose tested in Phase 2b, achieving 79% PASI 75 response. The Phase 3 dose of 200 mg QD was modeled to provide comparable daily exposure with improved convenience.
Icotrokinra reconstitution & storage
No reconstitution required. Icotrokinra is formulated as an oral tablet for direct administration. This is a key advantage over injectable peptides that require reconstitution.
Storage conditions for icotrokinra tablets have not been publicly disclosed in detail. Standard pharmaceutical oral tablet storage (room temperature, protected from moisture and light) is expected based on clinical trial protocols.
Icotrokinra dosing FAQ
How much bacteriostatic water should I add to a 15 mg vial of Icotrokinra?
The community standard is 2 mL of bacteriostatic water for a 15 mg Icotrokinra vial. That gives a concentration of 7.50 mg/mL, so a 200 mg dose is 2666.7 units on a U-100 insulin syringe. Adding 1 mL instead doubles the concentration to 15.00 mg/mL and halves the draw to 1333.3 units. Less water = smaller injection volume but harder to measure precisely.
How many syringe units is a 200 mg dose of Icotrokinra?
On a standard U-100 insulin syringe, a 200 mg dose of Icotrokinra is 2666.7 units when the 15 mg vial is reconstituted with 2 mL of bacteriostatic water (7.50 mg/mL). If you use 1 mL of bac water instead, draw 1333.3 units (15.00 mg/mL).
What is the standard Icotrokinra dose?
Clinical protocols for Icotrokinra typically use 200 mg once daily via subcutaneous injection. 200 mg is a common starting dose. This dose was used in all four Phase 3 ICONIC trials. Selected based on pharmacokinetic modeling from Phase 2b FRONTIER 1 data. Taken as a single daily tablet.
Where do you inject Icotrokinra?
Icotrokinra is typically administered subcutaneously. Common subcutaneous sites are the lower abdomen (at least an inch from the navel), the outer thigh, and the love handles. Rotate sites with each injection to reduce localized irritation and bruising.
Can I use sterile water instead of bacteriostatic water for Icotrokinra?
Bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) is strongly preferred for multi-dose vials like Icotrokinra because it inhibits microbial growth and lets a single vial be used over multiple weeks. Sterile water has no preservative and should generally be reserved for single-use preparations only.
More on Icotrokinra
Icotrokinra overview
Mechanism of action, primary uses, and research summary
Icotrokinra dosing protocols
Full clinical and research-based dosing reference
Icotrokinra community protocols
Real-world usage patterns from peptide communities
Icotrokinra side effects
Reported adverse effects and safety considerations
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.